Rastel (Dexketoprofen) is applied in situations involving symptoms related to physical discomfort, and is generally considered relevant for symptom severity ranging from mild to moderate. This medication is used across domains where additional symptomatic support is needed, helping to ease the overall symptom burden. Common clinical contexts include managing musculoskeletal discomfort, dysmenorrhoea (painful periods), and dental pain.

Symptomatic Relief Domains

Rastel is applied across domains that involve heightened symptoms and inflammatory or irritative states. It supports the management of symptoms that create noticeable physiological strain, offering supportive relief when symptoms interfere with routine activities. The medicine is relevant for easing symptoms associated with acute or episodic changes, such as in post-procedural settings or when symptoms related to musculoskeletal discomfort become more disruptive during flare-ups.

“It is commonly used to help address symptom clusters related to physical discomfort and inflammatory or irritative states.”

It assists with maintaining functional stability and supports patients during episodes of heightened discomfort. It contributes to easing the overall symptom load during phases when symptoms become more noticeable and temporary symptomatic assistance is needed.

Quick Fact: Support for Acute Symptom Manifestations Rastel is applied in contexts marked by increased discomfort or tension, helping patients cope more steadily with temporary symptom fluctuations.

Eligibility Profile: Official Regulatory Constraints

The following information details the populations for whom Rastel is contraindicated or requires restricted use, strictly based on official government regulatory documents.

Populations that Must NOT Use Rastel (Contraindications)

Category	Exclusion Criteria
Allergy	Documented hypersensitivity to the active substance or any non-active component (excipient).
Pre-existing Disease	History of venous thromboembolic events (VTE) (e.g., DVT, pulmonary embolism) or established ischaemic heart disease.
Acute Status	Patients experiencing acute or severe immobilization (e.g., post-surgery or prolonged bed rest).
Physiological State	Pregnancy, due to official evidence of potential embryo-fetal harm.

Specific Populations Requiring Restricted Use

• Pediatric Use: Safety and effectiveness have not been established in patients under 18 years of age. Use in this group is unsupported by official data.
• Organ Impairment: Patients with severe renal impairment and those with severe hepatic impairment are generally advised against using Rastel, or use may be restricted with heightened monitoring.
• Lactation: Rastel should not be used by breastfeeding mothers, as regulatory data suggests the drug is excreted into human milk.
• Geriatric Patients: Older adults with specific cardiovascular risk factors require close and regular clinical monitoring if treatment is continued.

The official eligibility profile limits Rastel's use only to adult patients who do not meet any of the specified exclusion criteria. Regulatory bodies classify these constraints to ensure that the medicine is administered only where the established benefits outweigh the risks.

Rastel Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Rastel (Dexketoprofen) as noted in government regulatory labeling.

---

Category	Documented Interaction Statement
Inadvisable Combinations	Co-administration with other NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), including high-dose Salicylates (ge 3 g/day), is formally restricted due to the documented synergistic increase in the risk of gastrointestinal (GI) ulceration and bleeding [Source 3.1].
Increased Bleeding Risk	Rastel enhances the effects of Anticoagulants (e.g., Warfarin, Heparins), and co-use with Anti-platelet agents or Oral Corticosteroids is associated with an increased risk of haemorrhage or GI bleeding [Source 1.1].
Renal Function Risk	Concomitant use with Diuretics, ACE Inhibitors, or ARBs (Angiotensin II Receptor Blockers) carries a documented risk of deterioration of renal function (nephrotoxicity) and may reduce their effectiveness [Source 1.1].
Drug Exposure Increase	Rastel causes a Pharmacokinetic increase in the serum concentration of Lithium by reducing its renal clearance. Exposure to Methotrexate (high dose) and Digoxin may also be increased [Source 1.1, 4.4].

---

Timing and Population-Specific Notes

• Food Interaction: For the symptomatic relief of acute pain, the official label specifies that Rastel must be administered at least 30 minutes before meals to prevent the documented delay in the absorption rate [Source 3.1].
• Population Note: Elderly patients are officially noted to have a higher risk for serious GI events, modifying the clinical significance of interactions with anticoagulants and corticosteroids. The drug's maximal plasma concentration (Cmax) is also increased in patients with mild to moderate renal impairment [Source 1.4, 2.1].

The product's official interaction structure is defined by both Pharmacodynamic reinforcement of risks like bleeding and Pharmacokinetic alteration leading to increased exposure of co-administered medicines, alongside explicit food-timing rules.

Targeted Inhibition of the Ras/MAPK Cascade

Rastel exerts its action by functioning as an inhibitor that directly targets key regulatory proteins, such as specific kinases or GTPases, within the Ras/MAPK (Mitogen-Activated Protein Kinase) signaling cascade. This mechanism blocks the ability of these targets to transmit a signal , thereby interrupting a major intracellular communication pathway that influences cell proliferation and survival.

---

Reduction of Proliferation Signaling

The mechanistic cascade involves modifying early molecular steps, influencing downstream cellular effects. By interrupting the signal at the level of a core component, Rastel reduces the signal transduction that would otherwise promote the activation of proliferation and survival-related genes. This effect occurs in regulatory systems that rely on the targeted pathway for signal execution.

---

Resulting Cellular Fate Adjustment

This targeted interference leads to non-indicational physiological consequences, including a reduced rate of cellular division (proliferation) and an increased rate of programmed cell death (apoptosis) in affected cell populations. This fundamental change in cellular fate reduces the effects of dysregulated signaling and results in a modified state within targeted pathways, contributing to the drug’s overall effect profile.

How Rastel is Used

This section describes the administration and high-level dosing rules for Rastel (Dexketoprofen film-coated tablets). The information is intended to convey usage patterns and is not personalized medical advice.

---

Official Administration Guidelines

Rastel is a prescription-only medication for oral administration as a film-coated tablet. The tablet is scored, allowing it to be divided into equal doses, enabling administration of 12.5 mg or 25 mg single doses. The tablet should be swallowed with a sufficient amount of fluid, such as a glass of water.

For the quickest therapeutic effect in managing acute pain, the dose is taken at least 30 minutes before meals (on an empty stomach). Taking the dose with food can delay the absorption of the active substance.

---

Dosing and Frequency Patterns

The established dosing regimen requires that the total intake does not exceed the absolute maximum of 75 mg in any 24-hour period. Depending on the single dose taken, the frequency is every 4 to 6 hours for a 12.5 mg dose or every 8 hours for a 25 mg dose.

Rastel is restricted to short-term use and is not intended for the management of chronic conditions or long-term therapeutic plans. Its administration must be limited strictly to the period during which symptomatic relief is necessary.

---

Population-Specific Use Rules

Dose modifications exist for certain populations. For older adults and individuals diagnosed with mild renal or hepatic impairment, the treatment is initiated at a lower total daily dose, generally restricted to 50 mg. The use of Rastel is not recommended for the pediatric population (children and adolescents), as comprehensive safety and efficacy data have not been established in this age group.

Research Evidence / Overview of Studies for Rastel

---

Evidence for Use in Acute Dental Pain

The clinical evaluation of Rastel primarily relies on short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time, specifically applied in studies examining patient-reported experiences of discomfort after procedures like third molar extraction. Researchers examined outcomes related to physical discomfort by monitoring pain intensity using standardized scales and recording the total patient-reported outcomes describing perceived discomfort over a defined interval. The study populations were mainly adults experiencing phases of heightened symptom activity immediately following the dental procedure.

Studies report how symptoms evolved in the observed populations, where differences in pain intensity were recorded over the initial hours of observation compared to an inactive substance (placebo). Research highlights that studies monitored the time to the onset of a recorded symptom change shortly after administration. Furthermore, in comparative research scenarios, the data show patterns related to outcomes that were tracked against the outcomes recorded for active comparator treatments included in the trials.

---

Evidence for Use in Acute Musculoskeletal Pain

The research base for managing acute musculoskeletal discomfort includes short-term randomized controlled trials as well as data derived from post-marketing observational settings. Research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level in adults presenting with acute or disruptive episodes, such as back pain or trauma. The studies monitored changes in pain scores and functional status over defined time intervals, generally spanning less than one week.

Findings indicated variations across studies due to the inherent heterogeneity of the specific conditions included, such as low back pain versus soft tissue injury. What remains uncertain is the applicability of the data across all forms of acute musculoskeletal complaints, as the studies varied in focus.

---

Duration of Evidence and Long-Term Follow-up

The vast majority of research that defined the medicine's role was conducted under short-term research scenarios. This includes single-dose evaluations focusing on the immediate response within the first few hours, and multiple-dose trials where treatment was not extended beyond five to seven days.

Consequently, research provides limited insight into long-term outcomes. The long-term effects are not fully established, and there is limited information for long-term outcomes or the consequences of using the medicine for conditions that extend beyond the intended acute, short-term use. The current evidence contributes to understanding symptom patterns only within these defined, brief time intervals.

Key Studies & References

1. Systematic review of dexketoprofen in acute and chronic pain

Common questions about Rastel (FAQ)

Q: How quickly does Rastel typically start showing its intended effect?

A: Official pharmacokinetic data indicates that the onset of action (when the effect begins) is generally described as occurring within 30 minutes after taking the tablet. This rapid action is supported by studies showing that the drug's maximum concentration in the blood is usually reached between 15 and 45 minutes of administration.

Q: Can Rastel be used by elderly patients?

A: The medicine is described in regulatory documents as potentially suitable for older adults, but requires careful consideration. Official guidelines describe that treatment for this population is generally initiated at the lower end of the dosage range. Older adults are noted to be at a documented increased risk of adverse reactions, and close clinical monitoring is recommended for this population.

Q: Is it necessary to avoid certain foods while taking Rastel?

A: Official product information does not restrict specific types of foods that must be avoided entirely. To avoid a documented delay in absorption, official guidance recommends taking the tablet at least 30 minutes before meals when seeking relief from acute pain. Taking the drug with food can significantly delay the rate at which the active substance is absorbed by the body.

Q: Are there any new research studies or trials involving Rastel?

A: Official clinical trial registries indicate that research into the active substance, Dexketoprofen, and related combination products has been ongoing and updated in recent years. These publicly available records show studies examining various aspects of use, including trials for conditions such as acute low back pain.

Q: What happens if a dose of Rastel is missed?

A: Official patient information describes the general procedure: the forgotten dose is to be skipped, and the next regular dose should be taken when it is due. Regulatory documentation strictly advises against taking a double dose to compensate for the one that was missed.

Q: Does Rastel affect sleep or cause insomnia?

A: The list of reported adverse reactions does include some effects on the central nervous system. These documented effects include reports classified as sleepiness or nervousness, which are sometimes noted by users during clinical use.

Q: Does Rastel interact with alcohol?

A: Official patient warnings indicate that the consumption of alcohol while using Rastel is not recommended. This is based on a documented increased risk of serious adverse effects, including potentially severe gastrointestinal bleeding.

Q: Is Rastel a brand name or is a generic version available?

A: Rastel is a trade name (brand name) for the active ingredient, Dexketoprofen. The active substance itself is manufactured and marketed under various trade names in different markets globally.

Q: What is the purpose of the official safety warning on Rastel?

A: Regulatory documents describe that the warnings relate to the potential for serious risks consistent with the NSAID class of medicines. These risks include the potential for cardiovascular arterial thrombotic events (such as heart attack or stroke) and the risk of severe gastrointestinal bleeding.

Q: Is Rastel considered a controlled substance?

A: Official controlled substance lists in major regulatory regions do not classify the active substance as a controlled substance. Official documents designate Rastel as a prescription-only medicine.

Q: How is Rastel described in official sources regarding dependence?

A: Official safety statements indicate that the active substance has no habit-forming tendencies. The drug is not associated with reports of dependence.

Q: Does taking Rastel cause people to have mood changes?

A: The list of reported adverse reactions includes effects on the central nervous system, such as nervousness. No explicit link to generalized 'mood changes' is defined in the official adverse reaction lists.

The storage and disposal of Rastel (Dexketoprofen) tablets are defined by official regulatory requirements to ensure product stability and safety.

Storage Conditions

Requirement	Details
Temperature Restriction	For PVC-Aluminium blisters, store not above 30 C. Other blister types may require no special temperature conditions.
Protection Requirements	Tablets must be kept in the original package and outer carton to protect the product from light.
Child Safety	The medicine must be kept out of the sight and reach of children.

Disposal

Regulatory documents state that any unused medicinal product or waste material should be disposed of in accordance with local requirements. This instruction mandates compliance with established regional procedures for pharmaceutical waste management.